Barritault Denis
About
Barritault Denis is from Greater Paris Metropolitan Region, France. Barritault is currently CEO at OTR3. Barritault also works as CEO OTR3 and emeritus professor Professor at OTR3 and university Paris Est Creteil, a job Barritault has held since Jan 2003. Another title Barritault currently holds is Professor at Université Paris-Est Créteil.
Go to finalscout.com and type Barritault Denis's name into the search box for a free email address. FinalScout is a professional database with more than 500 million business professionals and 200 million company executives.
Barritault Denis's current jobs
OTR3 was created to translate basic research to medicinal products based on a proprietary family of molecules called RGTA® (ReGeneraTing Agents), a new therapeutic class in regenerative medicine. RGTA are structural and functional mimetic of Heparan sulfate that restore in damaged tissue the cellular microenvironment, inductive to regeneration. Two products one for cornea and one for skin lesions have been on the market under trade names Cacipliq and Cacicol, several are in development including to reduce severity of lung damages in COVID 19
Founder and Director of " Laboratoire de Recherche sur la Croissance Cellulaire, la Réparation et la Régénération tissulaires" or CRRET. CNRS unit with 30 faculty members. Focus on Growth factors (FGF, HARP) and Glycoaminoglycans and mimetics with RGTA® , a Matrix therapy technology in regenerative medicine , Muscle regeneration.